Genes associate with abnormal bone cell activity in bone metastasis

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 569-578

  Roodman, G David ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastasis; Microenvironment; Myeloma; Osteoblasts; Osteoclasts

Indexed keywords

ACTIVIN A; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; DENOSUMAB; DICKKOPF 1 PROTEIN; DICKKOPF 1 PROTEIN MONOCLONAL ANTIBODY; ENDOTHELIN 1; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 7; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PREDNISONE; PROTEIN KINASE B; RAP 011; SCLEROSTIN; SCLEROSTIN ANTIBODY; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE; ZOLEDRONIC ACID;

ARTICLE; BONE CELL; BONE DESTRUCTION; BONE MARROW; BONE METASTASIS; CANCER GROWTH; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTIVINS; ANIMALS; ANNEXIN A2; BONE NEOPLASMS; CHEMOKINE CCL3; HUMANS; INTERLEUKIN-6; OSTEOBLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; RANK LIGAND;

EID: 84868001363     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9372-x     Document Type: Article

References (101)

1. Coleman, R. E. (2000). Management of bone metastases. The Oncologist, 5(6), 463-470.
2. Coleman, R. E. (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews, 27, 165-176.
3. Mundy, G. R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2, 584-593.
4. Lipton, A. (2004). Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. Journal of Supportive Oncology, 2(3), 205-213. discussion 213-214, 216-217, 219-220.
5. Rosen, L. S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M. A.; Coleman, R. E.; Reitsma, D. J.; Chen, B. L.; & Seaman, J. J. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98(8), 1735-1744.
6. Chirgwin, J. M.; & Guise, T. A. (2000). Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Critical Reviews in Eukaryotic Gene Expression, 10(2), 159-178.
7. Taube, T.; Elomaa, I.; Blomqvist, C.; et al. (1994). Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone, 15(2), 161-166.
8. Boyde A, Maconnachie E, Reid SA, et al. (1986). Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc (Pt 4), 1537-1554.
9. Fowler, J. A.; Edwards, C. M.; & Croucher, P. I. (2011). Tumor-host cell interactions in the bone disease of myeloma. Molecular mechanisms of breast cancer metastases to bone. Bone, 48(1), 121-128.
10. Guise, T. A.; Kozlow, W. M.; Heras-Herzig, A.; Padalecki, S. S.; Yin, J. J.; & Chirgwin, J. M. (2005). Molecular mechanisms of breast cancer metastases to bone. Clinical Breast Cancer, 5(Suppl(2)), S46-S53.
11. Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of Medicine, 350(16), 1655-1664.
12. Cackowski, F. C.; Anderson, J. L.; Patrene, K. D.; Choksi, R. J.; Shapiro, S. D.; Windle, J. J.; Blair, H. C.; & Roodman, G. D. (2010). Osteoclasts are important for bone angiogenesis. Blood, 115(1), 140-149.
13. Lacey, D. L.; Timms, E.; Tan, H. L.; et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93(2), 165-176.
14. Dougall, W. C.; Glaccum, M.; Charrier, K.; et al. (1999). RANK is essential for osteoclast and lymph node development. Genes & Development, 13(18), 2412-2424.
15. Sezer, O.; Heider, U.; Jakob, C.; et al. (2002). Human bone marrow myeloma cells express RANKL. Journal of Clinical Oncology, 20(1), 353-354.
16. Huang, L.; Cheng, Y. Y.; Chow, L. T. C.; Zheng, M. H.; & Kumta, S. M. (2002). Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Path, 55(11), 877-878.
17. Hofbauer, L. C.; Khosla, S.; Dunstan, C. R.; Lacey, D. L.; Boyle, W. J.; & Riggs, B. L. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research, 15(1), 2-12.
18. Fuller, K.; Wong, B.; Fox, S.; Choi, Y.; & Chambers, T. J. (1998). TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. The Journal of Experimental Medicine, 188(5), 997-1001.
19. Roodman, G. D. (1999). Cell biology of the osteoclast. Experimental Hematology, 27(8), 1229-1241.
20. Tsukii, K.; Shima, N.; Mochizuki, S.; et al. (1998). Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochemical and Biophysical Research Communications, 246(2), 337-341.
21. Hofbauer, L. C.; Neubauer, A.; & Heufelder, A. E. (2001). Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer, 92(3), 460-470.
22. Feng, X. (2005). RANKing intracellular signaling in osteoclasts. IUBMB Life, 57(6), 389-395.
23. Santos, V. R.; Lima, J. A.; Gonçalves, T. E.; Bastos, M. F.; Figueiredo, L. C.; Shibli, J. A.; & Duarte, P. M. (2010). Receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well-controlled type 2 diabetes. Journal of Periodontology, 81(10), 1455-1465.
24. Goranova-Marinova, V.; Goranov, S.; Pavlov, P.; & Tzvetkova, T. (2007). Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical Correlations. Haematologica, 92(7), 1000-1001.
25. Terpos, E.; Szydlo, R.; Apperley, J. F.; Hatjiharissi, E.; Politou, M.; Meletis, J.; Viniou, N.; Yataganas, X.; Goldman, J. M.; & Rahemtulla, A. (2003). Soluble receptor activator of nuclear factor KB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102(3), 1064-1069.
26. Canon, J.; Bryant, R.; Roudier, M.; Osgood, T.; Jones, J.; Miller, R.; Coxon, A.; Radinsky, R.; & Dougall, W. C. (2010). Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone, 46(6), 1613-1619.
27. Canon, J. R.; Roudier, M.; Bryant, R.; Morony, S.; Stolina, M.; Kostenuik, P. J.; & Dougall, W. C. (2008). Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clinical & Experimental Metastasis, 25(2), 119-129.
28. Tannehill-Gregg, S. H.; Levine, A. L.; Nadella, M. V.; Iguchi, H.; & Rosol, T. J. (2006). The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clinical & Experimental Metastasis, 23(1), 19-31.
29. Gonzalez-Suarez, E.; Jacob, A. P.; Jones, J.; Miller, R.; Roudier-Meyer, M. P.; Erwert, R.; Pinkas, J.; Branstetter, D.; & Dougall, W. C. (2010). RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature, 468(7320), 103-107.
30. Azim, H.; Michiels, S.; Bedard, P. L.; Singhal, S. K.; Criscitiello, C.; Ignatiadis, M.; Haibe-Kains, B.; Piccart, M. J.; Sotiriou, C.; & Loi, S. (2012). Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res, 18, 1341-1351.
31. Tang, Z. N.; Zhang, F.; Tang, P.; Qi, X. W.; & Jiang, J. (2011). RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation. Oncology Reports, 26(5), 1243-1250. doi: 10.3892/or.11.1368.
32. Jones, D. H.; Nakashima, T.; Sanchez, O. H.; Kozieradzki, I.; Komarova, S. V.; Sarosi, I.; Morony, S.; Rubin, E.; Sarao, R.; Hojilla, C. V.; Komnenovic, V.; Kong, Y. Y.; Schreiber, M.; Dixon, S. J.; Sims, S. M.; Khokha, R.; Wada, T.; & Penninger, J. M. (2006). Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 440(7084), 692-696.
33. Stopeck, A. T.; Lipton, A.; Body, J. J.; Steger, G. G.; Tonkin, K.; de Boer, R. H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D. A.; Viniega, M.; Fan, M.; Jiang, Q.; Dansey, R.; Jun, S.; & Braun, A. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind study. Journal of Clinical Oncology, 28(35), 5123-5129.
34. Fizazi, K.; Carducci, M.; Smith, M.; Damião, R.; Brown, J.; Karsh, L.; Milecki, P.; Shore, N.; Rader, M.; Wang, H.; Jiang, Q.; Tadros, S.; Dansey, R.; & Goessl, C. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet, 337(9768), 813-822.
35. Henry, D. H.; Costa, L.; Goldwasser, F.; Hirsh, V.; Hungria, V.; Prausova, J.; Scagliotti, G. V.; Sleeboom, H.; Spencer, A.; Vadhan-Raj, S.; von Moos, R.; Willenbacher, W.; Woll, P. J.; Wang, J.; Jiang, Q.; Jun, S.; Dansey, R.; & Yeh, H. (2011). Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology, 29(9), 1125-1132.
36. Choi, S. J.; Cruz, J. C.; Craig, F.; et al. (2000). Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood, 96(2), 671-675.
37. Han, J. H.; Choi, S. J.; Kurihara, N.; et al. (2001). Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood, 97(11), 3349-3353.
38. Choi, S. J.; Oba, Y.; Gazitt, Y.; et al. (2001). Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. The Journal of Clinical Investigation, 108(12), 1833-1841.
39. Oyajobi, B. O.; Franchin, G.; Williams, P. J.; et al. (2003). Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 102(1), 311-319.
40. Vallet, S.; Raje, N.; Ishitsuka, K.; Hideshima, T.; Podar, K.; Chhetri, S.; Pozzi, S.; Breitkreutz, I.; Kiziltepe, T.; Yasui, H.; Ocio, E. M.; Shiraishi, N.; Jin, J.; Okawa, Y.; Ikeda, H.; Mukherjee, S.; Vaghela, N.; Cirstea, D.; Ladetto, M.; Boccadoro, M.; & Anderson, K. C. (2007). MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood, 110(10), 3744-3752.
41. Oba, Y.; Lee, J. W.; Ehrlich, L. A.; Chung, H. Y.; Jelinek, D. F.; Callander, N. S.; Horuk, R.; Choi, S. J.; & Roodman, G. D. (2005). MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology, 33(3), 272-278.
42. Lentzsch, S.; Chatterjee, M.; Gries, M.; Bommert, K.; Gollasch, H.; Dörken, B.; & Bargou. (2004). RC PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia, 18(11), 1883-1890.
43. Roussou, M.; Tasidou, A.; Dimopoulos, M. A.; Kastritis, E.; Migkou, M.; Christoulas, D.; Gavriatopoulou, M.; Zagouri, F.; Matsouka, C.; Anagnostou, D.; & Terpos, E. (2009). Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia, 23(11), 2177-2181.
44. Terpos, E.; Politou, M.; Szydlo, R.; Goldman, J. M.; Apperley, J. F.; & Rahemtulla. (2003). A Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology, 123(1), 106-109.
45. Cross, N. A.; Hillman, L. S.; & Forte, L. R. (1998). The effects of calcium supplementation, duration of lactation, and time of day on concentrations of parathyroid hormone-related protein in human milk: a pilot study. Journal of Human Lactation, 14(2), 111-117.
46. Guise, T. A. (2000). Molecular mechanisms of osteolytic bone metastases. Cancer, 88(12 Suppl), 2892-2898.
47. Kremer, R.; Li, J.; Camirand, A.; & Karaplis, A. C. (2011). Parathyroid hormone related protein (PTHrP) in tumor progression. Advances in Experimental Medicine and Biology, 720, 145-160.
48. Yin, J. J.; Selander, K.; Chirgwin, J. M.; Dallas, M.; Grubbs, B. G.; Wieser, R.; Massagué, J.; Mundy, G. R.; & Guise, T. A. (1999). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. The Journal of Clinical Investigation, 103(2), 197-206.
49. Guise, T. A.; Yin, J. J.; Taylor, S. D.; Kumagai, Y.; Dallas, M.; Boyce, B. F.; Yoneda, T.; & Mundy, G. R. (1996). Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. The Journal of Clinical Investigation, 98(7), 1544-1549.
50. Tan, A. R.; Alexe, G.; & Reiss, M. (2008). Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Research and Treatment, 115(3), 453-495.
51. Jung, Y.; Wang, J.; Song, J.; et al. (2007). Annexin II expressed by osteoblasts andendothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood, 110(1), 82-90.
52. Rescher, U.; & Gerke, V. (2004). Annexins-unique membrane binding proteins with diverse functions. Journal of Cell Science, 117(Pt 13), 2631-2639.
53. Waisman, D. M. (1995). Annexin II tetramer: structure and function. Mol Cell Biochem, 149-150, 301-322.
54. Lu, G.; Maeda, H.; Reddy, S. V.; et al. (2006). Cloning and characterization of the annexin II receptor on human marrow stromal cells. Journal of Biological Chemistry, 281(41), 30542-30550.
55. Shiozawa, Y.; Havens, A. M.; Jung, Y.; et al. (2008). Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. Journal of Cellular Biochemistry, 105(2), 370-380.
56. Li, F.; Chung, H.; Reddy, S. V.; et al. (2005). Annexin II stimulates RANKL expression through MAPK. Journal of Bone and Mineral Research, 20(7), 1161-1167.
57. Takahashi, S.; Reddy, S. V.; Chirgwin, J. M.; et al. (1994). Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. Journal of Biological Chemistry, 269(46), 28696-28701.
58. Claudio, J. O.; Masih-Khan, E.; Tang, H.; et al. (2002). A molecular compendium of genes expressed in multiple myeloma. Blood, 100(6), 2175-2186.
59. Bao, H.; Jiang, M.; Zhu, M.; Sheng, F.; Ruan, J.; & Ruan, C. (2009). Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. International Journal of Hematology, 90(2), 177-185.
60. D'Souza, S.; Kurihara, N.; Shiozawa, Y.; Joseph, J.; Taichman, R.; Galson, D. L.; & Roodman, G. D. (2012). Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood, 119, 1888-1896.
61. Lee, J. W.; Chung, H. Y.; Ehrlich, L. A.; et al. (2004). IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood, 103(6), 2308-2315.
62. Rebecca Silbermann, Marina Bolzoni, Paola Storti, Benedetta Dalla Palma, Sabrina Bonomini, Judy Anderson, G. David Roodman, and Nicola Giuliani. (2011). Bone marrow monocyte/macrophage derived activin A mediates the osteoclastogenic effects of IL-3 in myeloma. Blood (ASH Annual Meeting Abstracts) 118: 3933.
63. Cheung, W. C.; & Van Ness, B. (2002). Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia, 16(6), 1182-1188.
64. de la Mata, J.; Uy, H. L.; Guise, T. A.; Story, B.; Boyce, B. F.; Mundy, G. R.; & Roodman, G. D. (1995). Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. The Journal of Clinical Investigation, 95(6), 2846-2852.
65. Gupta, D.; Treon, S. P.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y. T.; Lin, B.; Lentzsch, S.; Davies, F. E.; Chauhan, D.; Schlossman, R. L.; Richardson, P.; Ralph, P.; Wu, L.; Payvandi, F.; Muller, G.; Stirling, D. I.; & Anderson, K. C. (2001). Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15(12), 1950-1961.
66. Riancho, J. A.; & Mundy, G. R. (1995). The role of cytokines and growth factors as mediators of the effects of systemic hormones at the bone local level. Critical Reviews in Eukaryotic Gene Expression, 5(3-4), 193-217.
67. Raje, N.; & Roodman, G. D. (2011). Advances in the biology and treatment of bone disease in multiple myeloma. Clinical Cancer Research, 17(6), 1278-1286.
68. Li, X.; Pennisi, A.; & Yaccoby, S. (2008). Role of decorin in the antimyeloma effects of osteoblasts. Blood, 112(1), 159-168.
69. Yang, X.; & Karsenty, G. (2002). Transcription factors in bone: developmental and pathological aspects. Trends in Molecular Medicine, 8, 340.
70. Roodman, G. D. (2011). Osteoblast function in myeloma. Bone, 48(1), 135-140.
71. Tian, E.; Zhan, F.; Walker, R.; et al. (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine, 349(26), 2483-2494.
72. Yaccoby, S.; Ling, W.; Zhan, F.; Walker, R.; Barlogie, B.; & Shaughnessy, J. D.; Jr. (2007). Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 109(5), 2106-2111.
73. Fulciniti, M.; Tassone, P.; Hideshima, T.; et al. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.
74. Oshima, T.; Abe, M.; Asano, J.; et al. (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106(9), 3160-3165.
75. Ehrlich, L. A.; Chung, H. Y.; Ghobrial, I.; et al. (2005). IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 106(4), 1407-1414.
76. Giuliani, N.; Colla, S.; Morandi, F.; et al. (2005). Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 106(7), 2472-2483.
77. Hjorth-Hansen, H.; Seifert, M. F.; Börset, M.; Aarset, H.; Ostlie, A.; Sundan, A.; & Waage, A. (1999). Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Journal of Bone and Mineral Research, 14(2), 256-263.
78. Rokstad, A. M.; Holtan, S.; Strand, B.; Steinkjer, B.; Ryan, L.; Kulseng, B.; & Skjåk-Braek, G. (2002). Microencapsulation of cells producing therapeutic proteins: optimizing cell growth and secretion. TCell Transplant, 11(4), 313-324.
79. Kawasaki, T.; Niki, Y.; Miyamoto, T.; Horiuchi, K.; Matsumoto, M.; Aizawa, M.; & Toyama, Y. (2010). The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. Biomaterials, 31(6), 1191-1198.
80. Standal, T.; Abildgaard, N.; Fagerli, U. M.; Stordal, B.; Hjertner, O.; Borset, M.; & Sundan, A. (2007). HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood, 109(7), 3024-3030.
81. Hideshima, T.; Chauhan, D.; Podar, K.; Schlossman, R. L.; Richardson, P.; & Anderson, K. C. (2001). Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 28(6), 607-612.
82. Zhao, L.; Huang, J.; Zhang, H.; Wang, Y.; Matesic, L. E.; Takahata, M.; Awad, H.; Chen, D.; & Xing, L. (2011). Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells, 29(10), 1601-1610. doi: 10.1002/stem.703.
83. Olfa, G.; Christophe, C.; Philippe, L.; Romain, S.; Khaled, H.; Pierre, H.; Odile, B.; & Jean-Christophe, D. (2010). RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells. Bone, 46(4), 901-910.
84. Vallet, S.; Mukherjee, S.; Vaghela, N.; Hideshima, T.; Fulciniti, M.; Pozzi, S.; Santo, L.; Cirstea, D.; Patel, K.; Sohani, A. R.; Guimaraes, A.; Xie, W.; Chauhan, D.; Schoonmaker, J. A.; Attar, E.; Churchill, M.; Weller, E.; Munshi, N.; Seehra, J. S.; Weissleder, R.; Anderson, K. C.; Scadden, D. T.; & Raje, N. (2010). Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proceedings of the National Academy of Sciences of the United States of America, 107(11), 5124-5129.
85. Chantry, A. D.; Heath, D.; Mulivor, A. W.; Pearsall, S.; Baud'huin, M.; Coulton, L.; Evans, H.; Abdul, N.; Werner, E. D.; Bouxsein, M. L.; Key, M. L.; Seehra, J.; Arnett, T. R.; Vanderkerken, K.; & Croucher, P. (2010). Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research, 25(12), 2633-2646. doi: 10.1002/jbmr.142. Erratum in: J Bone Miner Res, 26(2), 439.
86. Lotinun, S.; Pearsall, R. S.; Davies, M. V.; Marvell, T. H.; Monnell, T. E.; Ucran, J.; Fajardo, R. J.; Kumar, R.; Underwood, K. W.; Seehra, J.; Bouxsein, M. L.; & Baron, R. (2010). A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone, 46(4), 1082-1088.
87. Abdulkadyrov KM, Salogub GN, Khuazheva NK, Woolf R, Haltom E, Borgstein NG, Knight R, Renshaw G, Yang Y, Sherman ML. (2009). ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis, American Society of Hematology (ASH) Meeting, Abstract 749.
88. Brunetti, G.; Oranger, A.; Mori, G.; Specchia, G.; Rinaldi, E.; Curci, P.; Zallone, A.; Rizzi, R.; Grano, M.; & Colucci, S. (2011). Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann NY Acad Sci, 1237, 19-23. doi: 10.1111/j.1749-6632.2011.06196.x.
89. Mendoza-Villanueva, D.; Zeef, L.; & Shore, P. (2011). Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Research, 13(5), R106.
90. van Lierop, A. H.; Hamdy, N. A.; Hamersma, H.; van Bezooijen, R. L.; Power, J.; Loveridge, N.; & Papapoulos, S. E. (2011). Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. Journal of Bone and Mineral Research, 26(12), 2804-2811. doi: 10.1002/jbmr.474.
91. Paszty, C.; Turner, C. H.; & Robinson, M. K. (2010). Sclerostin: a gem from the genome leads to bone-building antibodies. Journal of Bone and Mineral Research, 25(9), 1897-1904.
92. Terpos, E.; Christoulas, D.; Katodritou, E.; Bratengeier, C.; Gkotzamanidou, M.; Michalis, E.; Delimpasi, S.; Pouli, A.; Meletis, J.; Kastritis, E.; Zervas, K.; & Dimopoulos, M. A. (2011). Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. International Journal of Cancer. doi: 10.1002/ijc.27342.
93. D'Souza, S.; del Prete, D.; Jin, S.; Sun, Q.; Huston, A. J.; Kostov, F. E.; Sammut, B.; Hong, C. S.; Anderson, J. L.; Patrene, K. D.; Yu, S.; Velu, C. S.; Xiao, G.; Grimes, H. L.; Roodman, G. D.; & Galson, D. L. (2011). Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood, 118(26), 6871-6880.
94. Guise, T. A.; Yin, J. J.; & Mohammad, K. S. (2003). Role of endothelin-1 in osteoblastic bone metastases. Cancer, 97(3 Suppl), 779-784.
95. Granchi, S.; Brocchi, S.; Bonaccorsi, L.; Baldi, E.; Vinci, M. C.; Forti, G.; Serio, M.; & Maggi, M. (2001). Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate, 49(4), 267-277.
96. Clines, G. A.; Mohammad, K. S.; Bao, Y.; et al. (2007). Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology, 21(2), 486-498.
97. Yuyama, H.; Koakutsu, A.; Fujiyasu, N.; Tanahashi, M.; Fujimori, A.; Sato, S.; Shibasaki, K.; Tanaka, S.; Sudoh, K.; Sasamata, M.; & Miyata, K. (2004). Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. European Journal of Pharmacology, 492(2-3), 177-182.
98. Yi, B.; Williams, P. J.; Niewolna, M.; et al. (2002). Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Research, 62(3), 917-923.
99. Dai, J.; Keller, J.; Zhang, J.; et al. (2005). Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Research, 65(18), 8274-8285.
100. Hall, C. L.; Bafico, A.; Dai, J.; et al. (2005). Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Research, 65(17), 7554-7560.
101. Achbarou, A.; Kaiser, S.; Tremblay, G.; et al. (1994). Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Research, 54(9), 2372-2377.